Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 15

2216P - Clinicopathologic and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma

Date

21 Oct 2023

Session

Poster session 15

Topics

Tumour Site

Thyroid Cancer

Presenters

Soo Young Kim

Citation

Annals of Oncology (2023) 34 (suppl_2): S1145-S1151. 10.1016/S0923-7534(23)01270-X

Authors

S.Y. Kim1, S. Kim2, H.S. Chang2, Y.S. Lee3

Author affiliations

  • 1 Surgery, Ajou University Hospital School of Medicine, 443-749 - Suwon/KR
  • 2 Endocrine Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 06273 - Seoul/KR
  • 3 Department Of Surgery, Yonsei University, 03722 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2216P

Background

Diffuse sclerosing variant of papillary thyroid carcinoma (DSVPTC) is commonly observed in young patients, with a median age at diagnosis in the third decade of life. Further, the risk of recurrence is higher with DSVPTC than with classical papillary thyroid carcinoma (PTC). Therefore, this study aimed to describe the clinicopathological and genetic characteristics of patients of different ages with DSVPTC.

Methods

We retrospectively reviewed 397 patients who underwent thyroidectomy for DSVPTC at the Gangnam Severance Hospital, Yonsei University from January 2005 to December 2017. We selected 41 patients through random sampling by their age group, and examined mutations in 119 genes using next-generation sequencing.

Results

The mean age at diagnosis was 36.7±11.6 years, with the majority of patients (163, 41.1%) in their third decades. DSVPTC was predominant in women (276, 69.5%), compared with men. We observed recurrence in 46 patients (11.6%), with regional nodal recurrence being the most common recurrence site (32 patients, 69.6%). The tumour size increased in younger patients (<20 years: 2.69±1.56, 21–30 years: 1.88±1.30, and 31–40 years: 1.55±0.95), those displaying a plateau in their fourth (1.38±0.85) and fifth (1.29±0.91) decades, and those above 61 years of age (1.63±1.45). The initial presentation of cancer was more aggressive in paediatric patients with a larger size, more common multiplicity, and lateral neck metastasis. V-raf murine sarcoma viral oncogene homolog B1 (BRAF), Kirsten rat sarcoma virus (KRAS), and telomerase reverse transcriptase (TERT) displayed relatively higher mutations, compared with other genes.

Conclusions

DSVPTC displayed different clinical, pathological, and molecular profiles, compared with papillary thyroid carcinoma. BRAF, KRAS, and TERT were the most important genetic mutations, with differences depending on the age.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.